AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05141175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impedance Cardiography
Description: The ICG system provides a printed report that indicates whether a person's hemodynamic state is predominantly one that is vasoconstricted, hyperdynamic, or mixed
Study NCT05597241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apimostinel
Description: N-methyl-D-aspartate (NMDA) receptor modulator
Study NCT05597241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05219305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Implant Placement
Description: Placement in an edentulous site that was previously bone grafted in the prior study.
Study NCT04935320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0016878.HCl Solution 10 mg
Description: Oral solution fasted
Study NCT04935320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0016878.Citrate Capsule 10 mg
Description: Oral capsule fed or fasted
Study NCT06061536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipovirtide 10mg
Description: Lipovirtide 10mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；
Study NCT06061536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipovirtide 40mg
Description: Lipovirtide 40mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；
Study NCT06061536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipovirtide 60mg
Description: Lipovirtide 60mg+3TC+TDF（LP-80：once every 2 weeks；3TC+TDF：once daily）；
Study NCT06061536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: DTG +3TC + TDF（once daily）.
Study NCT05515081 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood sample collection
Description: blood sample colletion at regular intervals
Study NCT04713215 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: A short (approximately 20-minute) questionnaire will be administered to patients and carers who meet the inclusion criteria and who have expressed and interested, and consented to completing the questionnaire.
Study NCT05766423 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The PATTERN Intervention
Description: The intervention components include:~1. An adherence assessment that requests patients to self-report via MyChart about their medication use. The assessment provides a link between the health center and the patient ahead of a regularly scheduled clinic visit.~2. Care alert notifications directed to a nurse pool and/or member of the clinical care team when a medication adherence related problem is identified by the adherence assessment. The alert will also include the type of problem the patient is experiencing (cognitive, psychological, medical, regiment, social and/or economic). Once they receive these alerts, the care team can then activate appropriate staff and/or resources to respond.
Study NCT04702061 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spina plane block before general anaesthesia
Description: After skin infiltration with 2 ml of 2% lidocaine, an 18 G tuohy needle will be directed between the erector spina muscle and the transverse process of the T4 vertebra using the in-plane technique. The location of the needle will be confirmed by hydrodissection with saline after touching the transverse process. After the plan open, 5 ml of 2% lidocaine, 10 ml of 0.5% bupivacaine and 10 ml of saline, including hydrodissection, will be given in a total amount of 25 ml. Then a 20-G epidural catheter will be inserted 3-4 cm and fixed.
Study NCT04938089 — intervention group
Intervention type: OTHER
Intervention: Maintenance
Description: Regular compliant individual is defined in the study as a subject attending 100% of his/her recall visits with a maximum interval of 6 months. Irregular compliant individual is defined as a subject who missed at least one of the recall visits but continued to appear on an irregular basis with a maximum interval of 18 months, non-smoker individual is defined as a subject who never smoked, and lastly, smoker individual is defined as a subject who is smoking > 9 cigarettes per day.
Study NCT04702061 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural block before general anaesthesia
Description: After skin infiltration with 2 ml of 2% lidocaine, an 18 G tuohy needle will be entered through the T4-5 interspinous space (median or paramedian approach). After reaching the thoracic epidural area by loss of resistance method, the epidural catheter will be advanced and fixed to remain 3-4 cm in the epidural area. Following the test dose (2 ml of 2% lidocaine), 3 ml of 2% lidocaine, 5 ml of 0.5% bupivacaine and 5 ml of saline will be administered intermittently in a total volume of 15 ml.
Study NCT03716037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity for Life (PAL)
Description: The eight-week exercise program (The PAL Study) will incorporate balance, strength, endurance, and flexibility training. The duration of each exercise session, which will be offered three times a week, will be one hour. The supervised exercise session will include 30 minutes of moderate-intensity aerobic exercise, 15 minutes of resistance training, and 15 minutes of stretching and balance training
Study NCT05853068 — intervention group
Intervention type: DEVICE
Intervention: Mechanical ventilation
Description: Need for endotracheal intubation and invasive mechanical ventilation
Study NCT05120778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: as appear in arm description.
Study NCT05120778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional medical treatment
Description: participants will maintain habitual medical treatment prescribed by primary care and specialized physicians from the public health service.
Study NCT05541120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Patient Monitoring
Description: Remote patient monitoring as the intervention is defined as a tablet and Bluetooth-enabled glucometer technology that collects point-of-care (POC) blood glucose data from a patient outside of a traditional clinical setting, and securely transmits this data to Epic for review and potential intervention.
Study NCT05535699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: scapular exercise
Study NCT04797312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Free Anaesthesia protocol
Description: The OFA protocol begins with a systematic preoperative premedication with clonidine, continues with an adapted intraoperative management without opioid administration, but associating several molecules (clonidine, magnesium, lidocaine, ketamine) and ends with a continued administration of xylocaine up to 1 hour postoperatively in PACU. The use of an opioid in preoperative or intraoperative phases is considered as a deviation from the protocol.~To these different molecules, the use of hypnotic molecules left to the choice of the practitioner and a curare will be systematically associated.
Study NCT04797312 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: standard practice protocol based on the use of opioids (sufentanil or remifentanil)
Description: Standard anesthetic practices can be summed up as the combination of a hypnotic, a morphinic (sufentanil or remifentanil) and a curare. The use of ketamine is allowed.
Study NCT06328660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens 1
Description: Frequent replacement silicone hydrogel contact lens for 14 ± 3 days on a daily disposable wearing modality
Study NCT06328660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens 2
Description: Daily disposable silicone hydrogel contact lens for 14 ± 3 days on a daily disposable wearing modality
Study NCT04285710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: The key intervention aspect of this study is the application of 15 J/cm2 of 410 nm pulsed light directly onto the infected diabetic wounds of subjects every week over the course of 3 months, allowing for the cumulative exposure of around 180 J/cm2 for the entire study. This 15 J/cm2 weekly dosage of blue light will split up into two sessions every week, with each session applying 7.5 J/cm2 of light treatment. Phototherapy will be applied twice per week, with one phototherapy session occurring directly following the debridement surgery during the first visit of the week and the other session occurring after the study clinician removes the subjects wound dressings at the second visit.
Study NCT06455644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT group
Description: After completing the AF ablation, select the appropriate LAA occluder based on preoperative CT measurements for implantation.
Study NCT06455644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DSA group
Description: After completing the AF ablation, select the appropriate LAA occluder based on intraoperative DSA measurements for implantation.
Study NCT04285710 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Debridement Surgery and Wound Dressing
Description: All patients enrolled in the study will undergo standard care and treatment for infected diabetic wounds, which includes the weekly surgical removal of infected necrotic tissue from the diabetic wounds. In addition to debridement, both groups will utilize an antimicrobial wound dressing to cover and treat the infected diabetic wound. The subject's wounds will be dressed with Aquacel Ag Advantage Wound Dressings to protect and treat their diabetic wounds. These dressings will be changed twice a week by clinicians.
Study NCT04729972 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NT-501 CNTF implant
Description: Single implantation of CNTF-secreting NT-501 device into one eye
Study NCT04285710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Debridement Surgery and Wound Dressing
Description: All patients enrolled in the study will undergo standard care and treatment for infected diabetic wounds, which includes the weekly surgical removal of infected necrotic tissue from the diabetic wounds. In addition to debridement, both groups will utilize an antimicrobial wound dressing to cover and treat the infected diabetic wound. The subject's wounds will be dressed with Aquacel Ag Advantage Wound Dressings to protect and treat their diabetic wounds. These dressings will be changed twice a week by clinicians.
Study NCT05813184 — intervention group
Intervention type: DRUG
Intervention: Antibiotics
Description: Any antibiotic therapy administered > 7 days
Study NCT05894356 — intervention group
Intervention type: OTHER
Intervention: Study chart review
Description: Evaluation of 4250 sperm DNA fragmentation samples with the goal of defining a cut-off age beyond which SDF levels increase significantly
Study NCT05822037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT0594CP
Description: Cell injection
Study NCT05389397 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Outreach
Description: Mailed letter, secure message or telephone outreach will be used depending on arm enrolled
Study NCT05389397 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Outreach
Description: Mailed letter, secure message or telephone outreach will be used depending on arm enrolled
Study NCT06354530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib
Description: Drug: Camrelizumab 200mg on Day 1 of each 3-week cycle for 2 cycles during the neoadjuvant period~Drug: Carboplatin Area under the curve of 5 on Day 1 of each 3-week cycle for 2 cycles~Drug: Cisplatin 75 mg/m2 on Day 1 of each 3-week cycle, for 2 cycles~Drug: Paclitaxel 135-175 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: Nab-Paclitaxel 220-260 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: anlotinib 8 mg/day orally (from days 1 to 14 in a 21-day cycle) for 2 cycles
Study NCT06354530 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Description: Drug: Camrelizumab 200mg on Day 1 of each 3-week cycle for 2 cycles during the neoadjuvant period~Drug: Carboplatin Area under the curve of 5 on Day 1 of each 3-week cycle for 2 cycles~Drug: Cisplatin 75 mg/m2 on Day 1 of each 3-week cycle, for 2 cycles~Drug: Paclitaxel 135-175 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: Nab-Paclitaxel 220-260 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Thoracic radiotherapy RT once daily (from cycle 1 \[C1D1\], 41.4Gy/23Fx, 1.8Gy daily, for 4.6 weeks, 5 days/week)
Study NCT04809519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative Nursing based Multimodal Interventions for Uncontrolled Hypertensives
Description: In this study, multimodal interventions including yoga, meditation, and breathing techniques, compliance training for hypertension treatment, and home blood pressure measurement training will be applied to the experimental group.
Study NCT04809519 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ongoing treatment
Description: The ongoing health service of the control group will continue. In addition, the control group will be directed to a specialist doctor and standard brochures prepared by the Ministry of Health for hypertensive individuals will be given.
Study NCT05285761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of extended information on the conduct of complementary feeding
Description: Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.~In addition to the paper brochure and the generic information, parents in the intervention group will also receive the new recommendations relating to CF through an educational device (in the form of a smartphone application). This app will deliver information and very short videos illustrating various aspects of responsive feeding during CF and taking up the themes of the paper brochure. These 106 messages will be delivered regularly from the 3rd months until the 36th months of the child.
Study NCT05285761 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provision of current official information on complementary feeding
Description: Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will also receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.
Study NCT05900505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Navigator
Description: The social navigator will assess patient/family needs and help them to access community resources (specific to their community) to address these, while promoting their engagement and self-efficacy.
Study NCT06525688 — intervention group
Intervention type: OTHER
Intervention: Bone, Serum and Plasma sample
Description: Intervention: Bone samples will be collected during surgery from the femoral neck (which is typically removed and discarded in these operations) and fasting morning blood samples.
Study NCT05447936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Jarlsberg cheese
Description: Jarlsberg cheese is a regular cheese for free sale in grocery stores. The allotted amount of cheese was taken orally each day
Study NCT05279183 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Erythritol
Description: Subject specific dose of erythritol dissolved in 300 mL tap water.
Study NCT05279183 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: 30 g sucrose dissolved in 300 mL tap water.
Study NCT05279183 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucralose
Description: Subject specific dose of sucralose dissolved in 300 mL tap water.
Study NCT06497998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical characterization
Description: The oocyte is placed in a culture dish with IVF culture medium. This procedure is similar to that used in the ICSI procedure, except that the injection pipette is replaced by a glass indenter. The indenter (sterile, single-use, blunt-edged glass cylinder, L:16mm, ø:0.85mm, mass:8mg) is completely decoupled from the micromanipulation and microinjection platform and driven by the principle of a magnetic spring with negative stiffness.~The oocyte is immobilized using a restraining pipette to prevent unwanted movement during measurement.~The main objective is to investigate the prognostic value of parameters derived from kinetic measurements of microforces on mature human oocytes in the context of IVF with ICSI.~On each oocyte the mechanical testing is divided in 4 successive loading unloading phase to measure:~* global elasticity of the oocyte.~* global viscosity behaviour of the oocyte.~* local elasticity of the oocyte.~* local viscosity behaviour of the pellucid membrane.
Study NCT04600726 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no interventioni
Study NCT04734769 — intervention group
Intervention type: OTHER
Intervention: Collect retrospectively clinical data on reproductive outcomes
Description: Collect retrospectively clinical data on reproductive outcomes
Study NCT06460831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcatheter
Description: The microcatheter group undergoes alcohol ablation using a microcatheter.
Study NCT06460831 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: OTW
Description: The OTW group undergoes alcohol ablation using an OTW balloon.
Study NCT04989881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci Simulator
Description: Single training session
Study NCT04989881 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laparascopic training box
Description: Single training session
Study NCT06374901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Preoperative treatment with Tislelizumab
Study NCT06374901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX/XELOX
Description: Preoperative treatment with SOX/XELOX
Study NCT06374901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOX/XELOX
Description: Preoperative treatment with SOX/XELOX
Study NCT05597358 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Laser Therapy (HILT)
Description: Nd:Yag 1064 nm pulsed high intensity laser will be applied to the vulvar area.
Study NCT05597358 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Sham High Intensity Laser Therapy
Description: Nd:Yag 1064 pulsed high intensity laser deactivated probe will be applied to the vulvar area.
Study NCT05933967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib+R-CHOP
Description: Orelabrutinib 150mg qd PO. Rituximab 375 mg/m2 IV on Day 0 of each 21-day cycle. The CHOP include cyclophosphamide, doxorubicin/Epirubicin/liposomal doxorubicin, vincristine/Vindesine, and prednison.
Study NCT04492241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution
Description: TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Study Arm Component: Ginkgo Leaf Extract and Armillariella Mellea Powder, konjac (sweetener), purified water.
Study NCT04492241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution
Description: TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Placebo Arm Component: Caramel color (food color), konjac (sweetener), sucrose octaacetate (food additive), sodium benzoate (food additive), purified water.
Study NCT04884750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECA-ACE Vaccination Promotion Intervention
Description: A smartphone-based embodied conversational agent that educates users and motivates them to obtain vaccinations for SARS-CoV-2 and Influenza, according to Boston Public Health Commission guidelines.
Study NCT05662540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography/Magnetic Resonance (PET/MR)
Description: 18F-FDG PET/MR imaging (manufacturer: Siemens, model: Biography mMR). Research devices are marketed products.
Study NCT05449041 — intervention group
Intervention type: DEVICE
Intervention: Bulbicam
Description: Measurement of eye pressure; Accuracy diagram; Contrast chart; Visual field, Pupil size
Study NCT04768205 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesio tape
Description: The Kinesio tex tape is a medical tape that had been certified and patented.
Study NCT04768205 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio tape
Description: The Kinesio tex tape is a medical tape that had been certified and patented.
Study NCT05082519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IDEAL2 Intervention
Description: Intervention of diet and exercise to improve outcomes for ALL patients
Study NCT05955664 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: MRI indlcuding DTI
Description: A novel technique in MR imaging, which allows tracking of the pelvic floor muscle fibers, Diffusion Tensor Imaging (DTI) will be performed in addition to the standard scanning protocol. We think that MRI with DTI is superior to routine MRI in visualization of LAM.